One stock that might be an intriguing choice for investors right now is Denali Therapeutics Inc. DNLI. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
 
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 75 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Denali is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Denali Therapeutics Inc. Price and ConsensusDenali Therapeutics Inc. Price and Consensus

Denali Therapeutics Inc. price-consensus-chart | Denali Therapeutics Inc. Quote

In fact, over the past month, current quarter estimates have risen from a loss of 77 cents per share to a loss of 73 cents per share, while current year estimates have risen from a loss of $3.03 per share to a loss of $2.90 per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Denali. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Denali Therapeutics Inc. (DNLI):Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments